Stevanato Group (NYSE:STVN) Releases FY24 Earnings Guidance

Stevanato Group (NYSE:STVN) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of €0.47-0.49 for the period, compared to the consensus estimate of $0.48. The company issued revenue guidance of €1.09-1.11 billion, compared to the consensus revenue estimate of $1.09 billion. Stevanato Group also updated its FY 2024 guidance to 0.517-0.539 EPS.

Stevanato Group Stock Performance

NYSE:STVN traded up €0.05 ($0.05) during trading hours on Wednesday, reaching €22.55 ($24.78). The company had a trading volume of 669,300 shares, compared to its average volume of 511,327. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.13 and a current ratio of 1.74. The stock has a 50-day moving average of €19.61 and a two-hundred day moving average of €20.30. Stevanato Group has a one year low of €16.56 ($18.20) and a one year high of €34.73 ($38.16).

Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Tuesday, August 6th. The company reported €0.09 ($0.10) EPS for the quarter, missing analysts’ consensus estimates of €0.10 ($0.11) by (€0.01) (($0.01)). The business had revenue of €259.60 million during the quarter, compared to analyst estimates of €254.92 million. Stevanato Group had a return on equity of 10.89% and a net margin of 11.27%. Stevanato Group’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.15 EPS. As a group, research analysts predict that Stevanato Group will post 0.5 EPS for the current fiscal year.

Analysts Set New Price Targets

STVN has been the subject of a number of recent analyst reports. Citigroup dropped their price objective on Stevanato Group from $30.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, August 7th. Morgan Stanley dropped their price objective on Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, July 15th.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.